At the 10th World Congress on Lung Cancer (WCLC) in Vancouver, Canada Monday, 11 August 2003 from 10.15 to 11.45
According to the World Health Organisation (WHO) more than 6 million people worldwide die every year as a result of cancer, the second most prevalent cause of death in the developing world. Lung cancer is the most common cancer worldwide among men and women accounting for 1.1 million deaths each year, yet there are very few patient advocacy groups in the world specifically dedicated to this devastating disease. International experts will convene at the 10th World Conference on Lung Cancer (WCLC) in Vancouver, Canada, from 10-14 August to discuss new approaches in providing patients with more therapeutic options.
Alimta®* is a promising new therapy option for the treatment of non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). Gemzar® is currently standard treatment in many parts of the world as in combination therapy with cisplatin for NSCLC.
Breathing New Life into Lung Cancer Media Summit will feature international experts speaking about ongoing efforts by clinicians and researchers to offer therapy options that create positive outcomes for patients, as well as the increasingly important role of patient advocacy. Clinical data presented at the media summit will discuss the role of Gemzar® and Alimta® as valuable additions to the therapeutic landscape.
Breathing New Life into Lung Cancer Treatment Media Summit & Webcast (www.OncoLink.org) will include presentations from:
Monday 11 August 2003 from 10.15 to 11.45
Room 20, Vancouver Exhibit and Convention Centre
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2016 Trustees of The University of Pennsylvania